España

España:


  1. CYP2D6

Benítez J, LLerena A, Cobaleda J. Debrisoquin oxidation polymorphism in a Spanish population. Clin Pharmacol Ther. 1988 Jul;44(1):74-7.

Henthorn TK, Benitez J, Avram MJ, Martinez C, Llerena A, Cobaleda J, Krejcie TC, Gibbons RD. Assessment of the debrisoquin and dextromethorphan phenotyping tests by gaussian mixture distributions analysis. Clin Pharmacol Ther. 1989 Mar;45(3):328-33.

Menoyo A, del Rio E, Baiget M. Characterization of variant alleles of cytochrome CYP2D6 in a Spanish population. Cell Biochem Funct. 2006 Sep-Oct;24(5):381-5.

Llerena A, Edman G, Cobaleda J, Benítez J, Schalling D, Bertilsson L. Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr Scand. 1993 Jan;87(1):23-8.

Crescenti A, Mas S, Gassó P, Baiget M, Bernardo M, Lafuente A. Simultaneous genotyping of CYP2D6*3, *4, *5 and *6 polymorphisms in a Spanish population through multiplex long polymerase chain reaction and minisequencing multiplex single base extension analysis. Clin Exp Pharmacol Physiol. 2007 Oct;34(10):992-7.

  1. CYP2C19

Reviriego J, Bertilsson L, Carrillo JA, Llerena A, Valdivielso MJ, Benítez J. Frequency of S-mephenytoin hydroxylation deficiency in 373 Spanish subjects compared to other Caucasian populations. Eur J Clin Pharmacol. 1993;44(6):593-5.

  1. CYP2C8

Martínez C, García-Martín E, Blanco G, Gamito FJ, Ladero JM, Agúndez JA. The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. Br J Clin Pharmacol. 2005 Jan;59(1):62-9.

García-Martín E, Martínez C, Tabarés B, Frías J, Agúndez JA. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin Pharmacol Ther. 2004 Aug;76(2):119-27.ABSTRACT; NO PDF

López-Rodríguez R, Novalbos J, Gallego-Sandín S, Román-Martínez M, Torrado J, Gisbert JP, Abad-Santos F. Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers. Pharmacol Res. 2008 Jul;58(1):77-84.

Dorado P, Cavaco I, Cáceres MC, Piedade R, Ribeiro V, Llerena A. Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers. Eur J Clin Pharmacol. 2008 Oct;64(10):967-70.

  1. CYP2C9

Dorado P, Berecz R, Norberto MJ, Yasar U, Dahl ML, LLerena A. CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers. Eur J Clin Pharmacol. 2003 Jul;59(3):221-5.

Dorado P, Peñas-Lledó EM, González AP, Cáceres MC, Cobaleda J, Llerena A. Increased risk for major depression associated with the short allele of the serotonin transporter promoter region (5-HTTLPR-S) and the 02. CYP2C9*3 allele. Fundam Clin Pharmacol. 2007 Aug;21(4):451-3.

Dorado P, Sosa-Macias MG, Peñas-Lledó EM, Alanis-Bañuelos RE, Wong ML, Licinio J, Lares-Asseff I, Llerena A. CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards. Pharmacogenomics J. 2011 Apr;11(2):108-12.

García-Martín E, Martínez C, Ladero JM, Gamito FJ, Agúndez JA. High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population. Eur J Clin Pharmacol. 2001 Apr;57(1):47-9.ABSTRACT; NO PDF

García-Martín E, Martínez C, Tabarés B, Frías J, Agúndez JA. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin Pharmacol Ther. 2004 Aug;76(2):119-27. ABSTRACT; NO PDF

López-Rodríguez R, Novalbos J, Gallego-Sandín S, Román-Martínez M, Torrado J, Gisbert JP, Abad-Santos F. Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers. Pharmacol Res. 2008 Jul;58(1):77-84.

  1. CYP2A6

Oscarson M, Gullstén H, Rautio A, Bernal ML, Sinues B, Dahl ML, Stengård JH, Pelkonen O, Raunio H, Ingelman-Sundberg M. Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. FEBS Lett. 1998 Nov 6;438(3):201-5.

Soriano A, Vicente J, Carcas C, Gonzalez-Andrade F, Arenaz I, Martinez-Jarreta B, Fanlo A, Mayayo E, Sinués B. Differences between Spaniards and Ecuadorians in CYP2A6 allele frequencies: comparison with other populations. Fundam Clin Pharmacol. 2011 Oct;25(5):627-32.

  1. CYP2B6

Arenaz I, Vicente J, Fanlo A, Vásquez P, Medina JC, Conde B, González-Andrade F, Sinués B. Haplotype structure and allele frequencies of CYP2B6 in Spaniards and Central Americans. Fundam Clin Pharmacol. 2010 Apr;24(2):247-53.

  1. NAT2

Agúndez JA, Rodríguez I, Olivera M, Ladero JM, García MA, Ribera JM, Benítez J. CYP2D6, NAT2 and CYP2E1 genetic polymorphisms in nonagenarians. Age Ageing. 1997 Mar;26(2):147-51.

González MV, Alvarez V, Pello MF, Menéndez MJ, Suárez C, Coto E. Genetic polymorphism of N-acetyltransferase-2, glutathione S-transferase-M1, and cytochromes P450IIE1 and P450IID6 in the susceptibility to head and neck cancer. J Clin Pathol. 1998 Apr;51(4):294-8.

  1. CYP2E1

Agúndez JA, Rodríguez I, Olivera M, Ladero JM, García MA, Ribera JM, Benítez J. CYP2D6, NAT2 and CYP2E1 genetic polymorphisms in nonagenarians. Age Ageing. 1997 Mar;26(2):147-51.

Bolufer P, Collado M, Barragán E, Cervera J, Calasanz MJ, Colomer D, Roman-Gómez J, Sanz MA. The potential effect of gender in combination with common genetic polymorphisms of drug-metabolizing enzymes on the risk of developing acute leukemia. Haematologica. 2007 Mar;92(3):308-14.

González MV, Alvarez V, Pello MF, Menéndez MJ, Suárez C, Coto E. Genetic polymorphism of N-acetyltransferase-2, glutathione S-transferase-M1, and cytochromes P450IIE1 and P450IID6 in the susceptibility to head and neck cancer. J Clin Pathol. 1998 Apr;51(4):294-8.

Ladero JM, Agúndez JA, Rodríguez-Lescure A, Diaz-Rubio M, Benítez J. RsaI polymorphism at the cytochrome P4502E1 locus and risk of hepatocellular carcinoma. Gut. 1996 Aug;39(2):330-3.

  1. CYP2B6

Arenaza I, Vicentea J, Fanloa A, Vásquez P, Medinac JC, Conded B, González-Andrade F, Sinués B. 2010. Haplotype structure and allele frequencies of CYP2B6 in Spaniards and Central Americans. Fundamental & Clinical Pharmacology 24: 247–253.

Oscarsona M, Gullsteènb H, Rautiob A, Bernalc ML, Sinués B, Dahl M-L, Stengaîrde JH, Pelkonenb O, Rauniob H, Ingelman-Sundberg M. 1998. Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. FEBS Letters 438: 201-205.

  1. CYP3A4

García-Martín E, Martínez C, Pizarro RM, García-Gamito FJ, Gullsten H, Raunio H, Agúndez JA. CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin Pharmacol Ther. 2002 Mar;71(3):196-204. ABSTRACT; NO PDF

Gervasini G, Vizcaino S, Gasiba C, Carrillo JA, Benitez J. Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and Other Caucasian populations. Ther Drug Monit. 2005 Dec;27(6):819-21.ABSTRACT; NO PDF

Gervasini G, García-Martín E, Ladero JM, Pizarro R, Sastre J, Martínez C, García M, Diaz-Rubio M, Agúndez JA. Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients. BMC Cancer. 2007 Jul 2;7:118.

Sinues B, Vicente J, Fanlo A, Vasquez P, Medina JC, Mayayo E, Conde B, Arenaz I, Martinez-Jarreta B. CYP3A5*3 and CYP3A4*1B allele distribution and genotype combinations: differences between Spaniards and Central Americans. Ther Drug Monit. 2007 Aug;29(4):412-6.ABSTRACT; NO PDF

  1. CYP3A5

Sinues B, Vicente J, Fanlo A, Vasquez P, Medina JC, Mayayo E, Conde B, Arenaz I, Martinez-Jarreta B. CYP3A5*3 and CYP3A4*1B allele distribution and genotype combinations: differences between Spaniards and Central Americans. Ther Drug Monit. 2007 Aug;29(4):412-6.ABSTRACT; NO PDF

Gervasini G, Vizcaino S, Gasiba C, Carrillo JA, Benitez J. Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and Other Caucasian populations. Ther Drug Monit. 2005 Dec;27(6):819-21. ABSTRACT; NO PDF

Gervasini G, García-Martín E, Ladero JM, Pizarro R, Sastre J, Martínez C, García M, Diaz-Rubio M, Agúndez JA. Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients. BMC Cancer. 2007 Jul 2;7:118.

  1. CYP1A1

Esteller M, García A, Martínez-Palones JM, Xercavins J, Reventós J. Susceptibility to endometrial cancer: influence of allelism at p53, glutathione S-transferase (GSTM1 and GSTT1) and cytochrome P-450 (CYP1A1) loci. Br J Cancer. 1997;75(9):1385-8.

  1. GSTM1

González MV, Alvarez V, Pello MF, Menéndez MJ, Suárez C, Coto E. Genetic polymorphism of N-acetyltransferase-2, glutathione S-transferase-M1, and cytochromes P450IIE1 and P450IID6 in the susceptibility to head and neck cancer. J Clin Pathol. 1998 Apr;51(4):294-8.

Esteller M, García A, Martínez-Palones JM, Xercavins J, Reventós J. Susceptibility to endometrial cancer: influence of allelism at p53, glutathione S-transferase (GSTM1 and GSTT1) and cytochrome P-450 (CYP1A1) loci. Br J Cancer. 1997;75(9):1385-8.

  1. GSTT1

Esteller M, García A, Martínez-Palones JM, Xercavins J, Reventós J. Susceptibility to endometrial cancer: influence of allelism at p53, glutathione S-transferase (GSTM1 and GSTT1) and cytochrome P-450 (CYP1A1) loci. Br J Cancer. 1997;75(9):1385-8.

  1. CYP1A2

Gervasini G, Ghotbi R, Aklillu E, San Jose C, Cabanillas A, Kishikawa J, Benitez J, Carrillo JA. Haplotypes in the 5′-untranslated region of the CYP1A2 gene are inversely associated with lung cancer risk but do not correlate with caffeine metabolism. Environ Mol Mutagen. 2013 Mar;54(2):124-32.

  1. UGT

López M, Dorado P, Ortega A, Peñas-Lledó E, Monroy N, Silva-Zolezzi I, Cobaleda J, Gallego-Aguilera A, Alonso ME, Llerena A. Interethnic differences in UGT1A4 genetic polymorphisms between Mexican Mestizo and Spanish populations. Mol Biol Rep. 2013 Apr;40(4):3187-92.

  1. TP53

Esteller M, García A, Martínez-Palones JM, Xercavins J, Reventós J. Susceptibility to endometrial cancer: influence of allelism at p53, glutathione S-transferase (GSTM1 and GSTT1) and cytochrome P-450 (CYP1A1) loci. Br J Cancer. 1997;75(9):1385-8.

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.plugin cookies

ACEPTAR
Aviso de cookies